Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)
- 31 August 2017
- journal article
- research article
- Published by Elsevier BV in Lung Cancer
- Vol. 111, 23-29
- https://doi.org/10.1016/j.lungcan.2017.06.014
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Uncovering the role of p53 splice variants in human malignancy: a clinical perspectiveOncoTargets and Therapy, 2013
- The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysisNucleic Acids Research, 2012
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- p53 Modulates Acquired Resistance to EGFR Inhibitors and RadiationCancer Research, 2011
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- TP53 Mutations in Nonsmall Cell Lung CancerJournal of Biomedicine and Biotechnology, 2011
- Detection of Mutations inEGFRin Circulating Lung-Cancer CellsThe New England Journal of Medicine, 2008
- TP53Mutations and Survival in Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2007
- The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.Clinical Cancer Research, 2006